RBC Capital upgraded Bio-Techne, citing M&A confidence, margin gains, and growth potential after a sharp stock drop and alignment with sector valuations.
Latest Ratings for TECH
DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Sep 2021KeybancUpgradesSector WeightOverweight Jun 2021SVB LeerinkMaintainsOutperform